WORCESTER, Mass., Aug. 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) ( www.generex.com ), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has created a scientific advisory board in an effort to further its drug development programs, specifically in the areas of oncology and metabolic diseases. Management of Generex has been in late stage talks with a number of key industry leaders in the pharmaceutical and biotechnology industry to assist the Company in positioning its more later stage drug delivery and vaccine programs for commercialization and to further the advancement of its rich pipeline of metabolic and oncology related programs.
"We believe we are at the cusp of several significant advancements toward the commercial realization for the sciences we have been developing at our Company since our inception. We are confident that now is the time to bring a number of industry leaders together to help to guide our Company down the path to commercial success," stated Anna Gluskin, the Company's President & Chief Executive Officer. "We have been in discussions with some current industry leaders in oncology and metabolic diseases and we look forward to bringing in a group of professionals capable of providing us with the additional experience and insight to help us deliver on the promise of our strong pipeline of life improving drug programs."
About Generex Biotechnology CorporationGenerex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com . The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831 Safe Harbor Statement This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: American Capital Ventures, Inc. Investor Relations Contact: Howard Gostfrand 1-877-918-0774 Beckerman Public Relations Media Contact: Christina Brozek 201-465-8002